Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 261Gynecologic 6Tumor-Agnostic 4Thoracic 4Other solid neoplasm 4Breast 3Dermatologic 2NET 1Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Cisplatin 619pembrolizumab 323Radiotherapy 319Cetuximab 274Docetaxel 220Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 74Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 48Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 43tislelizumab 42Standard of Care 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Folfox protocol × Head & Neck × Clear all
NCT03526835 2025-01-29

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Merus B.V.

Phase 1/2 Recruiting
523 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡